Form D · Biotechnology
XYLOCOR THERAPEUTICS, INC.
Malvern, PA · CIK 0001690467
Offering snapshot reported Jan 20, 2021 · SEC filing
- Reported sold
- $4M Indefinite offering
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 14, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 20, 2021 | Initial | $4,000,000 | No comparison | 5 | SEC filing |
| Oct 17, 2018 | Initial | $16,800,000 | No comparison | 7 | SEC filing |
| Jul 26, 2018 | Initial | $200,000 | No comparison | 1 | SEC filing |
| Mar 19, 2018 | Initial | $60,000 | No comparison | 4 | SEC filing |
| Dec 6, 2017 | Initial | $100,000 | No comparison | 1 | SEC filing |
| Nov 21, 2016 | Initial | $250,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-386787
Source: Form D, filed Jan 20, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Fouad Azzam, Ph.D. | Director |
| Glenn Batchelder | Director |
| James Cohen | Director |
| Albert Gianchetti | Director, Executive |
| Aidan King | Director |
| Michael F. Powell, Ph.D. | Director |
| Todd Rosengart | Director |
| Todd K. Rosengart, M.D. | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
39 Addison Lane
Malvern, PA, 19355
Malvern, PA, 19355